In September 2013, the assets of bankrupt Polymedix were acquired by Cellceutix Corporation (OTCBB: CTIX). Effectively now out of business, PolyMedix, Inc had been a clinical-stage biotechnology company engaged in developing small-molecule drugs for the treatment of serious acute care conditions. The Company had created defensin mimetic antibiotic compounds, heparin antagonist compounds, and other drug compounds intended for human therapeutic. The Company had internally created a pipeline of infectious disease, cancer supportive care and cardiovascular product candidates. The Companys product included PMX-30063 and PMX-60056 and other PMX defensin-mimetics. In February 2011, the Company completed and announced positive results from a randomized, double-blind, placebo-controlled Phase I exposure-escalation clinical study where it evaluated the safety and pharmacokinetics of PMX-30063 in once-daily dosing up to 14 days.
